Search the Newsreel

CarGurus (NasdaqGS:CARG) Stock Price

CarGurus (NasdaqGS:CARG) is currently valued at US$37.94, which is 3.1% undervalued compared to its fair value of US$39.15. The company is focusing on dealer network expansion and premium tier adoption to drive future performance, and recent Q2 results have led analysts to raise the …

CarGurus Inc (CARG) Earnings Forecast: Future EPS & Revenue Growth Estimates

CarGurus Inc (CARG) has an earnings forecast score of 7.50, ranking 238th in the Software & IT Services industry, with an average price target of $40.50 from 16 analysts who largely recommend a "Buy" trend. The company's expected revenue for the next quarter is …

GURU Organic Energy Corp (GUU) Q4 2022 Earnings Report - Results, Call & Slides

Analysts’ Opinions Are Mixed on These Consumer Cyclical Stocks: Fox Factory Holding (FOXF) and CarGurus (CARG)

Analysts have issued mixed ratings for two consumer cyclical stocks: Fox Factory Holding (FOXF) and CarGurus (CARG). Fox Factory Holding received a "Hold" rating from Roth MKM analyst Scott Stember and a similar upgrade from TipRanks – Anthropic, with a consensus price target indicating …

Aurubis AG (AIAGY) (Q3 2026) Earnings Call Highlights: Strong Earnings Growth Amid Strategic ...

This article first appeared on GuruFocus. Revenue: Group revenues increased by 29% to EUR17.8 billion in the first nine months of fiscal year 2025-2026. Operating EBT: Increased by 31% to EUR374 million for the first nine months; Q3 operating EBT came in at EUR149 …

Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE …

Arcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk

CarGurus, Inc. SEC Filing (Aug 7, 2026) | CARG Form 144

This article details an SEC Form 144 filing by CarGurus, Inc. (CARG) on August 7, 2026. The filing indicates a proposed sale of 1100 shares of Class A common stock by an individual, acquired through restricted stock vesting in 2019, with an aggregate market …

Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside

Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains …

China Yurun Board Sets August Meeting on Interim Results and Dividend

GURU Organic Energy Corp (GUU) Q4 2023 Earnings Report - Results, Call & Slides

CarGurus (NASDAQ:CARG) Sets New 52-Week High on Better-Than-Expected Earnings

GURU Organic Energy Corp (GUU) Q3 2025 Earnings Report - Results, Call & Slides

GURU Organic Energy Corp (GUU) Q2 2025 Earnings Report - Results, Call & Slides

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20

CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVE® and …

CarGurus, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CARG) 2026-08-07

Earnings Flash (CARG) CarGurus, Inc. Reports Q2 Revenue $251.0M, vs. FactSet Est of $249.9M

CarGurus, Inc. (CARG) announced its Q2 revenue reached $251.0 million, surpassing FactSet's estimate of $249.9 million. The company also reported Q2 adjusted EPS of $0.66 per share, exceeding FactSet's estimate of $0.61. Furthermore, CarGurus provided Q3 revenue guidance between $253.5 million and $258.5 million …

Is CarGurus Inc (CARG) Undervalued After Q2 Earnings Beat? EPS: $0.50, Revenue: $251.0M, GF Score: 87/100

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view

Arcturus Therapeutics reported a narrower-than-expected loss for Q2 2026, beating EPS forecasts by 20%, but saw a significant revenue drop due to the conclusion of its CSL Seqirus collaboration. The company emphasized progress in its rare disease pipeline, including cystic fibrosis (ARCT-032) and ornithine …

Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary

Arcturus Therapeutics Holdings Inc. (ARCT) reported its Q2 2026 financial results, with revenue of $2.96 million and a net loss of $23.79 million, resulting in a diluted loss per share of $(0.84). This decline in revenue is attributed to KOSTAIVE transitioning to commercial stages, …

CarGurus Q2 Earnings Call Highlights

CarGurus (NASDAQ:CARG) Issues Q3 2026 Earnings Guidance

Earnings call transcript: CarGurus tops Q2 2026 EPS forecast, shares jump 5.3%

CarGurus’s (NASDAQ:CARG) Q2 CY2026 Earnings Results: Revenue In Line With Expectations, Stock Soars

(CARG) CarGurus, Inc. Expects Q3 Adjusted EPS Range $0.63 - $0.69

CarGurus, Inc. (CARG) anticipates its Q3 adjusted EPS to be in the range of $0.63 to $0.69. This announcement follows their Q2 results where the company reported revenue of $251.0M, surpassing FactSet's estimate of $249.9M, and an adjusted EPS of $0.66 per share, also …

CarGurus, Inc.: CarGurus Announces Second Quarter 2026 Results

CarGurus, Inc. announced strong financial results for the second quarter ended June 30, 2026, with revenue growing 13% year-over-year to $251.0 million, surpassing guidance midpoint. The company reported GAAP net income from continuing operations of $49.2 million and non-GAAP adjusted EBITDA of $84.7 million, …

Aurum Proptech's Material Subsidiaries See Auditor Change as MSKA & Associates LLP Steps Down

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) reported a Q2 loss of $0.84 per share, surpassing the Zacks Consensus Estimate of a $1.07 loss, and beat revenue estimates with $2.96 million. Despite underperforming the S&P 500 year-to-date, the company has exceeded EPS estimates in three of the last …

Aurubis Aktie: Gewinnsprung hebt Prognose

Arcturus Therapeutics: Q2 Earnings Snapshot

CarGurus (Nasdaq: CARG) posts Q2 growth, halves revolver but extends to 2031

CarGurus (CARG) Reports Q2 Earnings: What Key Metrics Have to Say

Pacer Advisors Inc. Purchases 82,222 Shares of CarGurus, Inc. $CARG

Pacer Advisors Inc. significantly increased its stake in CarGurus, Inc. (NASDAQ:CARG) by 31.5% in the first quarter, purchasing 82,222 additional shares, bringing their total ownership to 342,949 shares valued at $11.7 million. This move contributes to institutional investors collectively holding 86.9% of the company's …

Why (ARCT) Price Action Is Critical for Tactical Trading

The article discusses the critical price action for Arcturus Therapeutics Holdings Inc. (ARCT) for tactical trading, highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 394.0:1 risk-reward setup targeting a 90.6% gain versus 0.2% risk and …

CarGurus (CARG) Reports Earnings Tomorrow: What To Expect